Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 16/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.50 |
| ▸ | HTR2A | P28223 | 6/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4442267 | 0.92 | SLC6A4 (0.47) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL4436450 | 0.89 | SLC6A4 (0.45) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL27794942 | 0.87 | SLC6A4 (0.48) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL4448137 | 0.84 | SLC6A4 (0.53) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL14774744 | 0.83 | MEN1 (0.48) | SLC6A4HTR2A | |
| SCHEMBL4440976 | 0.82 | SLC6A4 (0.42) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL4441929 | 0.82 | SLC6A4 (0.49) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL14774605 | 0.82 | PTGER1 (0.46) | NR3C1NR3C2 | |
| SCHEMBL4439241 | 0.81 | SLC6A4 (0.46) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL27773687 | 0.80 | SLC6A4 (0.45) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061754-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008115999-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | FECH, SLC10A1, SLC40A1 | SLC6A4 724/4885KCNH2 4463/4885HTR2A 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.